Videos

Holowatyj spoke about the molecular differences of early-onset colorectal cancer by race, while maintaining that race is a social construct, leading to a multitude of options for future research.

Andreana N. Holowatyj, PhD, MS, Emphasizes the Complexity of Her Research in Colorectal Cancer and Future Opportunities

Articles

Reducing caloric and nutrient intake for patients who were overweight or obese and undergoing induction for B-cell acute lymphoblastic leukemia was feasible and improved patient response, according to an early-phase trial.

Caloric and Nutrient Restrictions Positively Impacted Response for Overweight Patients With B-cell ALL

During an After Hours segment of Medical World News®, Loren Winters, MSN, ANP-BC, OCN, spoke about her passion for health and wellness, expressed through yoga instruction and Ayurvedic health coaching. 

Medical World News® After Hours: Nurse Practitioner Loren Winters Discusses Staying Balanced With Yoga and Ayurveda 

For the detection of oral squamous cell carcinoma and oropharyngeal cancer, a novel technology has been granted breakthrough device designation by the FDA.

AI Technology Platform With mRNA Analysis Designated as Breakthrough Device by FDA

The lead author from a study presented at the American Association for Cancer Research Annual Meeting 2021 explained the main findings regarding potential differences in tumor mutation burden by race in patients with early-onset colorectal cancer.

Andreana N. Holowatyj, PhD, MS, Details the Main Results of Research into Colorectal Cancer Disparities

CancerNetwork® spoke with Sanju Sinha of the National Cancer Institute about the resulting data from his research into sex differences associated with using tumor mutational burden to predict response to PD-1 inhibition.

NCI Investigator on the Results of a Study Exploring Sex Bias Related to TMB as a Biomarker of PD-1 Inhibitors

The 3-year follow-up analysis of 4 treatment groups who received CNS prophylaxis found a decreased incidence of CNS relapse for patients with high-risk diffuse large B-cell lymphoma, although the data were not statistically significant.

Real-World Data Suggest Systemic High-Dose and Intrathecal MTX Lower CNS Relapse Incidence for DLBCL

Data reported from the phase 3 POSEIDON trial are the first to demonstrate a statically significant overall survival benefit with tremelimumab.

Tremelimumab and Durvalumab Combo for Stage IV NSCLC Reaches Significance for OS 

The KATHERINE trial found a clinical benefit without increasing the risk of CNS recurrence for patients with HER2-positive early breast cancer treated with T-DM1.

Subgroup Analyses of KATHERINE Trial Promote T-DM1 Use in High-Risk Groups

Nurse Navigator Janeen Bazan, RN, OCN, BSN, talks about the 4R Care Sequence® and its impact on the care of patients with breast cancer at the 2021 Oncology Nursing Society Annual Congress.

All News